TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001
October 11, 2021 08:00 ET
|
TRACON Pharmaceuticals, Inc.
YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials sponsored by Eucure Biopharma in...
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 13, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference
September 02, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
August 09, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
August 03, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021
July 28, 2021 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million
July 21, 2021 22:30 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and...
TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
July 21, 2021 17:27 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and...